Figure 1 Flow chart diagram of high-risk group AF patients

Slides:



Advertisements
Similar presentations
ROCKET-AF Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial.
Advertisements

Efficacy and safety of apixaban compared with warfarin at different levels of INR control for stroke prevention in atrial fibrillation.
Substrate and Trigger Ablation for Reduction of Atrial Fibrillation (STAR AF): a randomized, multicentre, international trial by Atul Verma, Roberto Mantovan,
The ACTIVE Investigators. N Engl J Med 2009 Apr 3 [Epub]
Antithrombotic Trialists’ Collaboration An updated collaborative overview of randomised trials of antiplatelet therapy among high-risk patients.
Interventions for prevention of post-operative atrial fibrillation and its complications after cardiac surgery: a meta-analysis by David C. Burgess, Michael.
Bone marrow cells are a rich source of growth factors and cytokines: implications for cell therapy trials after myocardial infarction by Mortimer Korf-Klingebiel,
Risk profile and benefits from Gp IIb-IIIa inhibitors among patients with ST-segment elevation myocardial infarction treated with primary angioplasty:
One year follow-up after cryoballoon isolation of the pulmonary veins in patients with paroxysmal atrial fibrillation by Yves Van Belle, Petter Janse,
Amiodarone prophylaxis for atrial fibrillation of high-risk patients after coronary bypass grafting: a prospective, double-blinded, placebo-controlled,
Short stature is associated with coronary heart disease: a systematic review of the literature and a meta-analysis by Tuula A. Paajanen, Niku K.J. Oksala,
Date of download: 6/1/2016 Copyright © The American College of Cardiology. All rights reserved. From: Beta-Blockers and Outcome in Heart Failure and Atrial.
Date of download: 6/27/2016 Copyright © The American College of Cardiology. All rights reserved. From: Use and Outcomes of Triple Therapy Among Older Patients.
Date of download: 6/28/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Urinary Sodium and Potassium Excretion and Risk of.
Date of download: 7/1/2016 Copyright © The American College of Cardiology. All rights reserved. From: Transition of Patients From Blinded Study Drug to.
Randomized, non-inferiority trial of three limus agent- eluting stents with different polymer coatings: the Intracoronary Stenting and Angiographic Results:
Prospective randomized study comparing amiodarone vs. amiodarone plus losartan vs. amiodarone plus perindopril for the prevention of atrial fibrillation.
Date of download: 7/10/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Choice of Antithrombotic Therapy for Stroke Prevention.
Reduction in recurrent cardiovascular events with prasugrel compared with clopidogrel in patients with acute coronary syndromes from the TRITON-TIMI 38.
Date of download: 9/17/2016 Copyright © The American College of Cardiology. All rights reserved. From: Evidence That D-Dimer Levels Predict Subsequent.
Date of download: 9/18/2016 Copyright © The American College of Cardiology. All rights reserved. From: Gastrointestinal Bleeding in Patients With Atrial.
Comparison of Dabigatran and Warfarin in Patients With Atrial Fibrillation and Valvular Heart DiseaseClinical Perspective by Michael D. Ezekowitz, Rangadham.
High heart rate: a cardiovascular risk factor? by Stéphane Cook, Mario Togni, Marcus C. Schaub, Peter Wenaweser, and Otto M. Hess EHJ Volume 27(20):
From: Incidence, Predictive Factors, and Prognostic Value of New-Onset Atrial Fibrillation Following Transcatheter Aortic Valve Implantation J Am Coll.
Risk With Atrial Fibrillation: A Guy Thing?
Case 66 year old male with PMH of HTN, DM, ESRD on renal replacement TIW, stroke in 2011 with right side residual weakness, atrial fibrillation, currently.
Figure 2. CONSORT flow diagram.
Copyright © 2011 American Medical Association. All rights reserved.
Figure 2 Survival curves in the elderly vs. younger patients
From: Adjusted-Dose Warfarin versus Aspirin for Preventing Stroke in Patients with Atrial Fibrillation Ann Intern Med. 2007;147(8): doi: /
Figure 1 Flow diagram displaying the proportions of patients with troponin measurements available from all eligible patients and the resulting study population.
Figure 1 Ischaemic endpoints
Figure 1 Patient flow chart.
2016 Guidelines of the Taiwan Heart Rhythm Society and the Taiwan Society of Cardiology for the management of atrial fibrillation  Chern-En Chiang, Tsu-Juey.
Figure 2 Kaplan–Meier estimates of event-free survival (survival to the combined endpoint). From: Long-term outcomes of patients with acute myocardial.
Figure 3 One-year adverse events (death, post-discharge myocardial infarction, revascularization) after PCI according to patients who (A) would not have.
Figure 2 The incidence of new onset AF, strokes, heart failure, and mortality according to the BMI (/ person-years). (Left: BMI
Making Decisions About Antithrombotic Therapy in Heart Disease
Figure 1 The flowchart depicts the total number of procedures in the Western Denmark Heart Registry (WDHR) and the exclusion of patients; NPR, National.
Figure 1. Nonadherence to guidelines for prescribing antiplatelet and anticoagulant therapy in 144 patients with atrial fibrillation who attend a Spanish.
Figure 1 Flow chart of study selection.
Figure 1 Incidence and total numbers of SCD in patients with depressed LV systolic function and in patients with preserved LV function. The incidence of.
Figure 1 Study flow chart
Non-vitamin K antagonist oral anticoagulants (NOACs) for stroke prevention in Asian patients with atrial fibrillation: Time for a reappraisal  Gregory.
Oral Anticoagulation and Preventing Stent Thrombosis
Atrial Fibrillation and PCI
ACTIVE A Effects of Addition of Clopidogrel to Aspirin in Patients with Atrial Fibrillation who are Unsuitable for Vitamin K Antagonists.
When Is Adding Aspirin to NOACs Worth the Risk?
Nat. Rev. Cardiol. doi: /nrcardio
Nat. Rev. Cardiol. doi: /nrcardio
Selecting NOACs for High-Risk Patients
Figure 1 Antiplatelet and anticoagulant pathways
Nat. Rev. Cardiol. doi: /nrcardio
Gregory Y.H. Lip, MD, Jonathan L. Halperin, MD, Hung-Fat Tse, MD, PhD 
Figure 1 Diagram showing analysis flow of patient selection and treatment allocation of ONTARGET/TRANSCEND. Figure 1 Diagram showing analysis flow of patient.
Figure 1 Rates of complications and mortality during index admission for atrial fibrillation ablation for the overall ... Figure 1 Rates of complications.
Figure 1 Periprocedural myonecrosis and myocardial infarction after left main coronary artery revascularization with ... Figure 1 Periprocedural myonecrosis.
Efficacy and safety outcomes with NOAC compared with warfarin in NOAC patients with 14 457 years of risk and 49 418 warfarin patients with 75 747.
ACC 2003 Late Breaking Trials
Figure 1 Relationships between magnitude of antithrombotic benefit vs
Figure 1 A dot plot illustrating the correlation between the yearly absolute risk difference for both MACE and major ... Figure 1 A dot plot illustrating.
(A) Kaplan-Meier curve showing AF-free survival after a single procedure for patients grouped according to use of CT integration. (A) Kaplan-Meier curve.
Unless provided in the caption above, the following copyright applies to the content of this slide: Published on behalf of the European Society of Cardiology.
Figure 1 Patient selection
Combining Antiplatelet and Antithrombotic Therapy (Triple Therapy): What Are the Risks and Benefits?  Luis Alejandro Asencio, MD, Jennifer J. Huang, DO,
Figure 1 Patient selection.
Figure 8. Stroke prevention strategy in patients with AF
Omar Abdul-Jawad Altisent et al. JCIN 2016;9:
Gianluigi Savarese et al. JCHF 2016;4:
Presenter Disclosure Information
Presentation transcript:

Figure 1 Flow chart diagram of high-risk group AF patients Figure 1 Flow chart diagram of high-risk group AF patients. Loss of follow-up corresponds to those patients of whom no efficacy and safety data are available. IQR<sub>P25–P75</sub>=interquartile range. Anticoagulant therapy=INR range (2.0–3.0). Combined therapy=triflusal 600 mg/day plus anticoagulation for an INR of 1.4–2.4. From: Effect of antithrombotic therapy in patients with mitral stenosis and atrial fibrillation: a sub-analysis of NASPEAF randomized trial Eur Heart J. 2005:960-967. doi:10.1093/eurheartj/ehi667 Eur Heart J | © The European Society of Cardiology 2006. All rights reserved. For Permissions, please e-mail: journals.permissions@oxfordjournals.org

Figure 2 Survival curves free from vascular events (systemic embolism, stroke, myocardial infarction, sudden death, and death from bleeding) among high-risk group patients during combined antiplatelet plus anticoagulant or anticoagulant alone therapy. High risk=non-valvular with prior embolism and mitral stenosis with or without prior embolism patients. SE, standard error; n, number of cases at risk. From: Effect of antithrombotic therapy in patients with mitral stenosis and atrial fibrillation: a sub-analysis of NASPEAF randomized trial Eur Heart J. 2005:960-967. doi:10.1093/eurheartj/ehi667 Eur Heart J | © The European Society of Cardiology 2006. All rights reserved. For Permissions, please e-mail: journals.permissions@oxfordjournals.org

Figure 4 Survival curves free from vascular events (systemic embolism, stroke, myocardial infarction, sudden death, and death from bleeding) in non-valvular with prior embolism and valvular with/without prior embolism patients during anticoagulant or combined therapy: (A) during anticoagulant alone therapy and (B) during combined therapy. SE, standard error; n, number of patients at risk; Emb, embolism. From: Effect of antithrombotic therapy in patients with mitral stenosis and atrial fibrillation: a sub-analysis of NASPEAF randomized trial Eur Heart J. 2005:960-967. doi:10.1093/eurheartj/ehi667 Eur Heart J | © The European Society of Cardiology 2006. All rights reserved. For Permissions, please e-mail: journals.permissions@oxfordjournals.org

Figure 4 Survival curves free from vascular events (systemic embolism, stroke, myocardial infarction, sudden death, and death from bleeding) in non-valvular with prior embolism and valvular with/without prior embolism patients during anticoagulant or combined therapy: (A) during anticoagulant alone therapy and (B) during combined therapy. SE, standard error; n, number of patients at risk; Emb, embolism. From: Effect of antithrombotic therapy in patients with mitral stenosis and atrial fibrillation: a sub-analysis of NASPEAF randomized trial Eur Heart J. 2005:960-967. doi:10.1093/eurheartj/ehi667 Eur Heart J | © The European Society of Cardiology 2006. All rights reserved. For Permissions, please e-mail: journals.permissions@oxfordjournals.org

Figure 3 Survival curves free from vascular events (systemic embolism, stroke, myocardial infarction, sudden death, and death from bleeding) in the three sub-groups of the high-risk group patients during combined or anticoagulant therapy: (A) non-valvular AF patients with prior embolism and (B) mitral stenosis patients with or without prior embolism. Emb, embolism; SE, standard error; n, number of patients at risk. From: Effect of antithrombotic therapy in patients with mitral stenosis and atrial fibrillation: a sub-analysis of NASPEAF randomized trial Eur Heart J. 2005:960-967. doi:10.1093/eurheartj/ehi667 Eur Heart J | © The European Society of Cardiology 2006. All rights reserved. For Permissions, please e-mail: journals.permissions@oxfordjournals.org

Figure 3 Survival curves free from vascular events (systemic embolism, stroke, myocardial infarction, sudden death, and death from bleeding) in the three sub-groups of the high-risk group patients during combined or anticoagulant therapy: (A) non-valvular AF patients with prior embolism and (B) mitral stenosis patients with or without prior embolism. Emb, embolism; SE, standard error; n, number of patients at risk. From: Effect of antithrombotic therapy in patients with mitral stenosis and atrial fibrillation: a sub-analysis of NASPEAF randomized trial Eur Heart J. 2005:960-967. doi:10.1093/eurheartj/ehi667 Eur Heart J | © The European Society of Cardiology 2006. All rights reserved. For Permissions, please e-mail: journals.permissions@oxfordjournals.org

Feedback: Privacy Policy Feedback
Do Not Sell My Personal Information
About project: SlidePlayer Terms of Service

© 2025 SlidePlayer.com. Inc. All rights reserved.